A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease

NCT ID: NCT01028313

Last Updated: 2013-02-13

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL

Brief Summary

There is a clear need for effective, steroid-sparing agents for the management of chronic graft-versus-host disease (GVHD). Thus, agents like Histone deacetylase (HDAC) inhibitors, with the potential of decreasing pro-inflammatory events leading to GVHD without affecting graft-versus-leukemia (GVL), may have a central role in the prevention and treatment of GVHD.

This study will look at the efficacy of panobinostat (LBH589), an HDAC inhibitor, in the treatment of patients with chronic GVHD who have failed corticosteroids. In this group of patients, effective steroid-sparing options are limited and are usually associated with profound immunosuppression and decreased GVL effect.

Detailed Description

Chronic GVHD is an autoimmune, inflammatory disorder that occurs in the majority of patients who experience acute GVHD. Long-term corticosteroids are still standard therapy for chronic GVHD. Corticosteroids are associated with high morbidity and non-relapse mortality. In addition, corticosteroids are broadly immunosuppressive and can also decrease the GVL effect and increase the incidence of relapse. There is a clear need for effective, steroid-sparing agents for the management of chronic GVHD. Thus, agents like HDAC inhibitors, with the potential of decreasing pro-inflammatory events leading to GVHD without affecting GVL, may have a central role in the prevention and treatment of GVHD.

This study will look at the efficacy of panobinostat (LBH589), an HDAC inhibitor, in the treatment of patients with chronic GVHD who have failed corticosteroids. In this group of patients, effective steroid-sparing options are limited and are usually associated with profound immunosuppression and decreased GVL effect.

Conditions

Chronic Graft-Versus-Host Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Systemic Therapy

Group Type: EXPERIMENTAL

LBH589

Intervention Type: DRUG

20 mg PO three times weekly

Methylprednisolone

Intervention Type: DRUG

1 mg/kg/day PO continuously

Interventions

LBH589

20 mg PO three times weekly

Intervention Type: DRUG

Methylprednisolone

1 mg/kg/day PO continuously

Intervention Type: DRUG

Other Intervention Names

Panobinostat; Medrol, Depo-Medrol

Eligibility Criteria

Inclusion Criteria

1. Chronic GvHD following allogeneic HSCT of any source (bone marrow, peripheral blood, or cord blood stem cells), from any donor type (related, unrelated, or mismatched) and with any type of malignancy. Chronic GvHD will be defined according to NIH Consensus Criteria.

2. Patients must have had inadequate response to treatment with steroids and calcineurin inhibitors. Patients must have been treated with an initial dose of at least 1 mg/kg/day of methylprednisolone (MP) or equivalent in combination with tacrolimus or cyclosporine and must fulfill the definition of steroid refractoriness or resistance. Steroid refractoriness or resistance will be defined as:

1. Lack of any response after 1 month of treatment with MP, including 15 days of at least 0.5 mg/kg/day.

2. Worsening of existing GvHD or new organ involvement at any time following one week of initiation of MP at 1 mg/kg/day.

3. Reflare or worsening of GvHD at any time during steroid taper.

4. Patients should not have received any drug or treatment for chronic GvHD other than steroids and calcineurin inhibitors (i.e., cyclosporine or tacrolimus).

3. Patient must not have evidence of primary disease relapse.

4. An ECOG (Eastern Cooperative Oncology Group) performance status of ≤2

5. Baseline MUGA or ECHO must demonstrate left ventricular ejection fraction (LVEF) ≥40%.

6. No uncontrolled arrhythmias or symptoms of heart disease.

7. FEV1, FVC, and DLCO ≥40%.

8. Laboratory values as follows:

• white blood cell ≥2500/mm³;
• absolute neutrophil count (ANC) ≥1,000/mm³;
• hemoglobin ≥9.5 g%;
• platelets ≥50,000/mm³;
• total bilirubin <3 x upper limits of normal;
• aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5 × the institutional upper limit of normal (ULN);
• creatinine <1.5 × ULN or creatinine clearance ≥ 50 ml/min;
• serum potassium ≥ LLN;
• serum sodium ≥ LLN;
• serum calcium WNL;
• serum phosphorus WNL;
• serum magnesium WNL;

9. Patients with elevated alkaline phosphatase due to bone metastasis may be enrolled.

10. TSH and free T4 within normal limits (clinically euthyroid patients are permitted to receive thyroid supplements to treat underlying hypothyroidism).

11. Age ≥ 18 years, male or female.

12. Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria

1. Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer.

2. Patients who will need valproic acid for any medical condition during the study or ≤5 days prior to first panobinostat treatment.

3. Use of prior immunosuppressants other than steroids and calcineurin inhibitors(i.e. cyclosporine or tacrolimus).

4. Chronic active hepatitis or cirrhosis.

5. Impaired cardiac function including any of the following:

• Patients with congenital long QT syndrome;
• Patients with history or presence of sustained ventricular tachyarrhythmias;
• Patients with any history of ventricular fibrillation or Torsades de Pointes;
• Patients with bradycardia defined as HR <50 bpm. Patients with pacemakers are eligible if HR ≥50 bpm.
• Patients with myocardial infarction or unstable angina ≤6 months prior to starting study drug;
• Right bundle branch block plus left anterior hemiblock (bifasicular block);
• Screening ECG with QTc >450 msec;
• Congestive heart failure (CHF) > New York Heart Association (NYHA) Class II (see Appendix D).

6. Concomitant use of drugs with a risk of causing Torsades de Pointes (see Appendix A).

7. Other concurrent severe and/or uncontrolled medical conditions.

8. Any condition that impairs patient's ability to swallow whole pills or gastrointestinal (GI) tract disease that involves an inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: collaborator

SCRI Development Innovations, LLC

OTHER

Sponsor Role: lead

Responsible Party

SCRI Oncology Research Consortium

Principal Investigators

Daniel R Couriel, M.D.

Role: STUDY_CHAIR

SCRI Development Innovations, LLC

Locations

Tennessee Oncology, PLLC

Nashville, Tennessee, United States

Countries

United States

Other Identifiers

SCRI BMT 02

Identifier Type: -

Identifier Source: org_study_id